Evidence map›Paper›PMID 41693327›Full record

ReviewCurrent Alzheimer research2025

Neuroprotective Agents: Implications for Parkinson's Disease Treatment.

Khaled Ramadan Algantri, Wael Mohamed, Mohd Hamzah Mohd Nasir, Abdul Rahman Mahmoud Fata Nahas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current Alzheimer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Khaled Ramadan AlgantriDepartment of Anatomy, Kulliyyah of Medicine, Widad University College, BIM Point, Bandar Indera Mahkota, Kuantan, Pahang, 25200, Malaysia.
Wael MohamedDepartment of Basic Medical Science, Kulliyyah of Medicine, International Islamic University Malaysia, Bandar Indera Mahkota, Kuantan, Pahang, 25200, Malaysia.
Mohd Hamzah Mohd NasirDepartment of Biotechnology, Kulliyyah of Science, International Islamic University Malaysia, Bandar Indera Mahkota, Kuantan, 25200, Malaysia.
Abdul Rahman Mahmoud Fata NahasDepartment of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia, Bandar Indera Mahkota, Kuantan, Pahang, 25200, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a multifaceted neurodegenerative condition marked by the progressive loss of dopaminergic neurons, leading to impairments in movement and cognition. This study offers an in-depth examination of the pathophysiological pathways associated with PD, emphasising the roles of oxidative stress, mitochondrial dysfunction, and neuroinflammation. The study examines the interaction between genetic and environmental factors in the development of PD, highlighting the significance of oxidative stress, mitochondrial dysfunction, and excitotoxicity in the degeneration of dopaminergic neurons. It also looks into the impact of neuroinflammation and microglial activation on the causes of PD. Despite considerable progress in research, there remains a lack of effective treatments that can modify the course of the disease, highlighting the pressing need for new therapeutic approaches that address mitochondrial malfunction, oxidative stress, and neuroinflammation. This study assesses the neuroprotective efficacy of various substances, notably natural agents like resveratrol, curcumin, ginsenoside, and melatonin, for managing PD. Although these natural chemicals show promise, further robust clinical trials are needed to confirm their effectiveness and safety, as well as to investigate their potential incorporation into conventional PD treatment.

Indexed as

Neuroprotective AgentsParkinson DiseaseAnimalsCurcuminHumansMitochondriaNeuroinflammatory DiseasesOxidative StressCurcuminNeuroprotective Agentsbradykinesiamitochondrial dysfunction.Neuroprotective agentsParkinson’s disease (PD)reactive oxygen species (ROS)substantia nigra pars compacta (SNpc)

Identifiers

PMID41693327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.